002) were learn more associated with RVR. Among these factors, previous IFN response

(null-response, Odds ratio (OR):0.19, 95% CI:0.04-0.86, p = 0.031) and HCV RNA level (OR:0.29, 95% CI:0.10-0.81, p = 0.018) in Model 1 (including all 8 factors) and HCV RNA level (OR:0.40, 95% CI:0.17-0.95, p = 0.038) and IL28B SNP (rs8099917, TT vs. non-TT, OR:0.28, 95% CI:0.09-0.86, p = 0.026) in Model 2 (including 7 factors other than previous IFN history and response) were significantly associated with RVR in multivariate analysis. The RVR rates according to baseline characteristics were listed in table. The high RVR rates were obtained except NR among the elderly patients > 65 y.o.. Conclusion: In the triple therapy with SMV, Peg-IFN and RBV, the RVR rates were low in patients with non-responder, higher HCV RNA and IL28B non-TT. Naïve patients and relapsers with old age had a good response to this treatment. Table. The RVR rates according to baseline characteristics Disclosures: Eiji Mita – Grant/Research Support: MSD Tetsuo Takehara – Grant/Research www.selleckchem.com/products/R788(Fostamatinib-disodium).html Support: Chugai Pharmaceutical Co., MSD K.K. The following people have nothing to disclose: Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, Ryoko Yamada, Naoki Harada, Naoki Morishita, Yuki Tahata, Hayato Hikita, Ryotaro Sakamori, Takuya Miyagi, Yuichi Yoshida, Tomo-hide Tatsumi, Akira Yamada, Masahide Oshita,

Hideki Hagiwara, Toshifumi Ito, Yukinori Yamada, Taizo Hijioka, Shinji Tamura, Kazuhiro Katayama, Harumasa Yoshihara, Yasuharu Imai, Michio Kato, Norio Hayashi Background: HCV recurrence post liver transplantation is universal, 3-oxoacyl-(acyl-carrier-protein) reductase affecting the patient and graft survival. Sofosbuvir is a direct acting antiviral without interaction with Calcinurin inhibitor or MMF. In treatment of HCV genotype 1 and 4 Sofosbuvir can be used with ribavirin

alone for 24 weeks or in combination with peginterferon alfa-2a (Peg-INF) and ribavirin for 12 weeks duration. Method: This is a retrospective review of patients receiving Sofosbuvir based therapy in our center from February 2014 tell now for histologic HCV recurrence post liver transplant. Immunosuppression was mainly tacrlomius with or without MMF. 12 patients had Sofosbuvir, Ribavirin and Peg-INF (triple therapy), while 7 patients had Sofosbuvir, Rib-avirin without Peg-INF (dual therapy). Most patients had HCV recurrence stage 2 fibrosis or more on liver biopsy. Results: To date, a total of 19 patients were included. (12 genotype 4, 5 genotype 1b, 1 genotype 2, 1 mixed genotype). Mean Age was 58, and the cohort had 10 males. Mean baseline HCV RNA was 6.6 log10 IU/ml and 3 patients had graft cirrhosis. All patients were treatment experienced either before or after the liver transplant. Twelve patients were treated with triple therapy for 12 weeks, one patient treated with dual therapy for 12 weeks (genotype 2) and the remaining 6 patients were treated with dual therapy for 24 weeks.